Gilead Sciences (GILD) '4997 Data 'Impressive & Underappreciated', KOL Suggests - Jefferies; PT to $95

October 25, 2016 6:47 AM EDT
Get Alerts GILD Hot Sheet
Price: $73.07 -0.4%

Rating Summary:
    24 Buy, 11 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade GILD Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Jefferies analyst Brian Abrahams reiterated a Buy rating and bumped his price target on Gilead Sciences (NASDAQ: GILD) to $95.00 (from $93.00) as KOL feedback suggests '4997 data, while limited, was impressive and underappreciated.

Abrahams commented, "Following discussions with a NASH KOL, we believe the Street underappreciated the impressiveness of last week's ph.II '4997 data. While we acknowledge small pt numbers remain a meaningful limitation, given our feedback we believe it is appropriate to incorporate prob-adjusted out-year revs, which raises our PT by $2 to $95. We continue to believe HCV declines are baked in, and GILD shares do not reflect HIV stability and potential pipeline upside"

For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.

Shares of Gilead Sciences closed at $74.15 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, FDA, Hot Comments

Related Entities

Jefferies & Co

Add Your Comment